Health and Human Services Secretary Alex Azar said Thursday that Pfizer and its partner BioNTech would file for emergency use authorization of their experimental COVID-19 vaccine on Friday, and that he expects Moderna will soon follow with its candidate.
Pfizer confirmed in a press release that it and BioNTech will on Friday submit an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization of their vaccine candidate, called BNT162b2, a move that “will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020.”
